Avricore Health (AVCRF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for FY2024, filed Jun 16, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVCRF SEC filings page.
Avricore Health Inc (AVCRF) reported $3.3M in revenue for fiscal year 2024, up 25.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Avricore Health Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Avricore Health Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Avricore Health Inc reported a net loss of $465K while generating $698K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Avricore Health Inc generated $3.3M in revenue in fiscal year 2024. This represents an increase of 25.9% from the prior year.
Avricore Health Inc reported a net loss of $465K in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Avricore Health Inc earned -$0.01 per diluted share (EPS) in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Avricore Health Inc generated $572K in free cash flow in fiscal year 2024, representing cash available after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Avricore Health Inc held $786K in cash as of fiscal year 2024; no long-term debt figure is on record for that period.
Not reported for fiscal year 2024.
Margins & Returns
Avricore Health Inc's gross margin was 39.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 4.8 percentage points from the prior year.
Avricore Health Inc's net profit margin was -14.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 6.1 percentage points from the prior year.
Avricore Health Inc's ROE was -34.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.9 percentage points from the prior year.
Not reported for fiscal year 2024.
Capital Allocation
Avricore Health Inc invested $126K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 83.7% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
AVCRF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M+25.9% | $2.6M+102.0% | $1.3M+1259.6% | $96K+271.1% | $26K+1.7% | $25K+127.1% | $11Kn/m | $0-100.0% | $755K+16384.1% | $5K |
| Cost of Revenue | $2.0M+16.7% | $1.7M+78.3% | $969K+1241.9% | $72K+492.4% | $12K-14.6% | $14K+19.8% | $12Kn/m | $0-100.0% | $530K+26413.5% | $2K |
| Gross Profit | $1.3M+43.2% | $912K+170.0% | $338K+1313.1% | $24K+74.3% | $14K+22.5% | $11Kn/m | -$706n/m | $0-100.0% | $226K+8630.2% | $3K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | $184K-4.8% | $194K+24.5% | $156K+245.5% | $45K |
| Interest Expense | N/A | N/A | N/A | $17K-73.3% | $62K+1459.0% | $4K+5208.5% | $75n/m | $0n/m | $0n/m | $0 |
| Net Income | -$465Kn/m | -$531Kn/m | -$605Kn/m | -$1.3Mn/m | -$921K | N/A | -$3.0Mn/m | -$2.2Mn/m | -$1.9Mn/m | -$1.8M |
| EPS (Basic) | -$0.01n/m | -$0.01n/m | -$0.01n/m | -$0.02n/m | -$0.02n/m | -$0.03 | N/A | N/A | N/A | N/A |
| EPS (Diluted) | -$0.01n/m | -$0.01n/m | -$0.01n/m | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A |
| Diluted Shares (Avg) | 100M+0.8% | 100M+1.7% | 98M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: SG&A Expenses, Operating Income, EBITDA, Income Tax.
AVCRF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M-17.0% | $1.9M+1.3% | $1.9M+6.3% | $1.8M+417.4% | $345K+114.6% | $161K-81.7% | $880K-62.0% | $2.3M+36.7% | $1.7M | N/A |
| Current Assets | $1.1M+87.6% | $586K-44.6% | $1.1M-37.4% | $1.7M+389.7% | $345K+114.6% | $161K-70.9% | $552K-58.7% | $1.3M-20.0% | $1.7M | N/A |
| Cash & Equivalents | $786K+275.4% | $209K-54.3% | $459K-70.9% | $1.6M+563.7% | $237K+2129.7% | $11K-82.8% | $62K-86.2% | $447K+40.4% | $318K-85.4% | $2.2M |
| Inventory | $352-97.8% | $16K | N/A | N/A | N/A | $0-100.0% | $75K-55.5% | $169K-78.6% | $787K | N/A |
| Accounts Receivable | $291K-10.1% | $324K-43.1% | $569K+694.5% | $72K+666.1% | $9K-21.7% | $12K-94.2% | $205K-42.9% | $360K-32.8% | $536K | N/A |
| Goodwill | $41K+16.2% | $35K+60.1% | $22K-10.5% | $25K+1048188.4% | $2+1.6% | $2-100.0% | $312K-65.6% | $908Kn/m | $0 | N/A |
| Total Liabilities | $230K-42.7% | $401K-10.3% | $447K+576.1% | $66K-92.7% | $905K+74.1% | $520K+125.7% | $230K-28.3% | $321K+20.7% | $266K | N/A |
| Current Liabilities | N/A | N/A | $447K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Non-Current Liabilities | N/A | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | $30K+2.5% | $30K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.4M-10.2% | $1.5M+4.8% | $1.5M-15.6% | $1.7Mn/m | -$568Kn/m | -$359K-155.3% | $649K-67.5% | $2.0M+39.7% | $1.4M-46.9% | $2.7M |
| Retained Earnings | -$22.5Mn/m | -$24.0Mn/m | -$22.9Mn/m | -$23.6Mn/m | -$22.4Mn/m | -$21.1Mn/m | -$18.5Mn/m | -$16.9Mn/m | -$13.7Mn/m | -$11.7M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
AVCRF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $698K+39.5% | $500Kn/m | -$324Kn/m | -$966Kn/m | -$959Kn/m | -$530Kn/m | -$1.0Mn/m | -$831Kn/m | -$1.5Mn/m | -$1.2M |
| Capital Expenditures | $126K-83.7% | $774K-12.3% | $882K+969.5% | $82K | N/A | N/A | $4K+21.2% | $3K-36.0% | $5K-80.9% | $25K |
| Free Cash Flow | $572Kn/m | -$274Kn/m | -$1.2Mn/m | -$1.0M | N/A | N/A | -$1.0Mn/m | -$835Kn/m | -$1.5Mn/m | -$1.2M |
| Investing Cash Flow | -$143Kn/m | -$793Kn/m | -$893Kn/m | -$110Kn/m | $0n/m | $0n/m | -$110Kn/m | -$103Kn/m | -$5Kn/m | -$25K |
| Financing Cash Flow | $39K+22.1% | $32K-82.8% | $188K-92.2% | $2.4M+103.6% | $1.2M+149.6% | $475K-53.9% | $1.0M-36.6% | $1.6M+502.1% | $270K-91.5% | $3.2M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
AVCRF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.3%+4.8pp | 34.5%+8.7pp | 25.8%+1.0pp | 24.9%-28.1pp | 52.9%+9.0pp | 43.9%+50.2pp | -6.3% | N/A | 29.9%-26.5pp | 56.4% |
| Net Margin | -14.0%+6.1pp | -20.1%+26.2pp | -46.3% | -1390.9% | -3554.2% | N/A | -27046.8% | N/A | -257.9% | -38520.0% |
| Return on Equity | -34.0%+0.9pp | -34.9%+6.8pp | -41.7%+36.1pp | -77.8% | N/A | N/A | -466.9%-357.4pp | -109.5%+26.7pp | -136.3%-70.7pp | -65.6% |
| Return on Assets | -29.1%-1.5pp | -27.6%+4.2pp | -31.9%+43.0pp | -74.9%+191.9pp | -266.8% | N/A | -344.7%-250.3pp | -94.4%+20.5pp | -114.9% | N/A |
| Current Ratio | N/A | N/A | 2.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | N/A | 0.020.0x | 0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.17-0.1x | 0.260.0x | 0.31+0.3x | 0.04 | N/A | N/A | 0.35+0.2x | 0.160.0x | 0.19 | N/A |
| Asset Turnover | 2.08+0.7x | 1.37+0.7x | 0.69+0.6x | 0.050.0x | 0.08-0.1x | 0.16+0.1x | 0.010.0x | 0.00-0.4x | 0.45 | N/A |
| FCF Margin | 17.2%+27.6pp | -10.4%+81.9pp | -92.2% | -1090.7% | N/A | N/A | -9257.2% | N/A | -204.2% | -26525.9% |
Not reported in any period shown, so not listed: Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Avricore Health Inc AVCRF | FY2024 | $3.3M | -$465K | -14.0% | $101K | — |
| ProPhase Labs Inc PRPH | FY2025 | $4.3M | -$14.7M | N/A | $111K | — |
| Hypha Labs, Inc. FUNI | FY2025 | N/A | N/A | N/A | $570K | — |
| NovelStem Intl Corp NSTM | FY2025 | N/A | N/A | N/A | $345K | — |
Where Avricore Health Inc Ranks
Frequently Asked Questions
Avricore Health Inc (AVCRF) reported $3.3M in total revenue for fiscal year 2024. This represents a 25.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Avricore Health Inc (AVCRF) revenue grew by 25.9% year-over-year, from $2.6M to $3.3M in fiscal year 2024.
No, Avricore Health Inc (AVCRF) reported a net loss of $465K in fiscal year 2024, with a net profit margin of -14.0%.
Avricore Health Inc (AVCRF) had a gross margin of 39.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
Avricore Health Inc (AVCRF) had a net profit margin of -14.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
Avricore Health Inc (AVCRF) has a return on equity of -34.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
Avricore Health Inc (AVCRF) generated $572K in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Avricore Health Inc (AVCRF) generated $698K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
Avricore Health Inc (AVCRF) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.
Avricore Health Inc (AVCRF) invested $126K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
Avricore Health Inc (AVCRF) had a liabilities-to-equity ratio of 0.17 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
Avricore Health Inc (AVCRF) had a return on assets of -29.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Avricore Health Inc (AVCRF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $101K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Avricore Health Inc (AVCRF) trades at 0.0x sales, its market capitalization divided by $3.3M revenue, FY2024. The market capitalization is $101K as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Avricore Health Inc (AVCRF) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Avricore Health Inc (AVCRF) reported a net loss of $465K while generating $698K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.